Citations

Showing 10 of 108083 citations.

Sex Determines Cardiac Myocyte Stretch and Relaxation
Coronado, Michael J., Fairweather, DeLisa , Bruno, Katelyn A. , Fairweather, DeLisa , Bruno, Katelyn A

Mayo Clinic

Circulation: Cardiovascular Genetics | October 13, 2017 | Volume: 10 | Issue: 5 | Pages: No page available

10.1161/circgenetics.117.001950 | PMID 29030406 Get It

Overall survival in patients with glioblastoma before and after bevacizumab approval
Ravelo, Arliene , Sommer, Nicolas, Guérin, Annie , Ionescu‐Ittu, Raluca , Shi, Sherry, Macalalad, Alex, Uhm, Joon H. , Guerin, Annie , Johnson, Derek R. , Omuro, Antonio

Mayo Clinic

Current Medical Research and Opinion | October 13, 2017 | Volume: 34 | Issue: 5 | Pages: 813-820

10.1080/03007995.2017.1392294 | PMID 29025274 Get It

Revisiting the need for bone marrow examination in chronic myeloid leukemia
Tefferi, Ayalew , Hanson, Curtis A. , Ketterling, Rhett P. , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | October 13, 2017 | Volume: 93 | Issue: 1 | Pages: 5-7

10.1002/ajh.24942 | PMID 29027250 Get It

TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration‐Resistant Prostate Cancer
Liu, Duan , Wang, Liguo , Vedell, Peter T. , Niu, Nifang, Yu, Jia , Weinshilboum, Richard M. , Wang, Liewei , Kohli, Manish , Hillman, David W. , Wang, Liguo , Qin, Sisi , Weinshilboum, Richard M. , Liu, Duan

Mayo Clinic

Clinical Pharmacology & Therapeutics | October 13, 2017 | Volume: 104 | Issue: 1 | Pages: 201-210

10.1002/cpt.907 | PMID 29027195 Get It

The testis‐specific Y‐encoded‐like protein (TSPYL) gene family includes TSPYL1 to TSPYL6. We previously reported that TSPYL5 regulates cytochrome P450 (CYP) 19A1 expression. Here we show that TSPYLs, especially TSPYL 1, 2, and 4, can regulate the expression of many CYP genes, including CYP17A1, a key enzyme in androgen biosynthesis, and CYP3A4, an enzyme that catalyzes the metabolism of abiraterone, a CYP17 inhibitor. Furthermore, a common TSPYL1 single nucleotide polymorphism (SNP), rs3828743 (G/A) (Pro62Ser), abolishes TSPYL1's ability to suppress CYP3A4 expression, resulting in reduced abiraterone concentrations and increased cell proliferation. Data from a prospective clinical trial of 87 metastatic castration‐resistant prostate cancer patients treated with abiraterone acetate/prednisone showed that the variant SNP genotype (A) was significantly associated with worse response and progression‐free survival. In summary, TSPYL genes are novel CYP gene transcription regulators, and genetic alteration within these genes significantly influences response to drug therapy through transcriptional regulation of CYP450 genes.
PET/MRI: Where might it replace PET/CT?
Ehman, Eric C. , Johnson, Geoffrey B. , Leynes, Andrew P. , Johnson, Geoffrey B , Villanueva-Meyer, Javier E. , Cha, Soonmee , Larson, Peder E. Z. , Hope, Thomas A.

Mayo Clinic

Journal of Magnetic Resonance Imaging | October 13, 2017 | Volume: 46 | Issue: 5 | Pages: No page available

10.1002/jmri.25872 Get It

Low‐dose CT for the detection and classification of metastatic liver lesions: Results of the 2016 Low Dose CT Grand Challenge
Bartley, Adam C. , Carter, Rickey E. , Chen, Baiyu , Drees, Tammy A., Edwards, Phillip K , Holmes, David R. , Huang, Alice E. , Khan, Farhana, McMillan, Kyle, Michalak, Gregory J. , Nunez, Kristina M., Yu, Lifeng , Edwards, Phillip, McMillan, Kyle L, Carter, Rickey E , McCollough, Cynthia H. , Leng, Shuai , Yu, Lifeng , Fletcher, Joel G.

Mayo Clinic

Medical Physics | October 13, 2017 | Volume: 44 | Issue: 10 | Pages: No page available

10.1002/mp.12345 | PMID 29027235 Get It

Purpose Using common datasets, to estimate and compare the diagnostic performance of image‐based denoising techniques or iterative reconstruction algorithms for the task of detecting hepatic metastases. Methods Datasets from contrast‐enhanced CT scans of the liver were provided to participants in an NIH ‐, AAPM ‐ and Mayo Clinic‐sponsored Low Dose CT Grand Challenge. Training data included full‐dose and quarter‐dose scans of the ACR CT accreditation phantom and 10 patient examinations; both images and projections were provided in the training data. Projection data were supplied in a vendor‐neutral standardized format ( DICOM ‐ CT ‐ PD ). Twenty quarter‐dose patient datasets were provided to each participant for testing the performance of their technique. Images were provided to sites intending to perform denoising in the image domain. Fully preprocessed projection data and statistical noise maps were provided to sites intending to perform iterative reconstruction. Upon return of the denoised or iteratively reconstructed quarter‐dose images, randomized, blinded evaluation of the cases was performed using a Latin Square study design by 11 senior radiology residents or fellows, who marked the locations of identified hepatic metastases. Markings were scored against reference locations of clinically or pathologically demonstrated metastases to determine a per‐lesion normalized score and a per‐case normalized score (a faculty abdominal radiologist established the reference location using clinical and pathological information). Scores increased for correct detections; scores decreased for missed or incorrect detections. The winner for the competition was the entry that produced the highest total score (mean of the per‐lesion and per‐case normalized score). Reader confidence was used to compute a Jackknife alternative free‐response receiver operating characteristic ( JAFROC ) figure of merit, which was used for breaking ties. Results 103 participants from 90 sites and 26 countries registered to participate. Training data were shared with 77 sites that completed the data sharing agreements. Subsequently, 41 sites downloaded the 20 test cases, which included only the 25% dose data ( CTDI vol = 3.0 ± 1.8 mG y, SSDE = 3.5 ± 1.3 mG y). 22 sites submitted results for evaluation. One site provided binary images and one site provided images with severe artifacts; cases from these sites were excluded from review and the participants removed from the challenge. The mean (range) per‐lesion and per‐case normalized scores were −24.2% (−75.8%, 3%) and 47% (10%, 70%), respectively. Compared to reader results for commercially reconstructed quarter‐dose images with no noise reduction, 11 of the 20 sites showed a numeric improvement in the mean JAFROC figure of merit. Notably two sites performed comparably to the reader results for full‐dose commercial images. The study was not designed for these comparisons, so wide confidence intervals surrounded these figures of merit and the results should be used only to motivate future testing. Conclusion Infrastructure and methodology were developed to rapidly estimate observer performance for liver metastasis detection in low‐dose CT examinations of the liver after either image‐based denoising or iterative reconstruction. The results demonstrated large differences in detection and classification performance between noise reduction methods, although the majority of methods provided some improvement in performance relative to the commercial quarter‐dose images with no noise reduction applied.
Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine
Sterner, Rosalie M. , Kremer, Kimberly N. , Al‐Kali, Aref , Patnaik, Mrinal M. , Gangat, Naseema , Litzow, Mark R. , Wijnen, André J. van , Hedin, Karen E. , Kaufmann, Scott H. , van Wijnen, Andre J , Westendorf, Jennifer J.

Mayo Clinic

Oncotarget | October 12, 2017 | Volume: 8 | Issue: 55 | Pages: 94569-94579

10.18632/oncotarget.21809 | PMID 29212250 Get It

Relationship of Aortic Wall Distensibility to Mitral and Aortic Valve Calcification: The Multi-Ethnic Study of Atherosclerosis
Cohoon, Kevin P. , Criqui, Michael H. , Budoff, Matthew J. , Decker, Paul A. , Durazo, Ramón, Liu, Kiang , Budoff, Matthew , Lima, João A.C. , Blaha, Michael Joseph , Decker, Paul A. , Kramer, Holly

Mayo Clinic

Angiology | October 12, 2017 | Volume: 69 | Issue: 5 | Pages: 443-448

10.1177/0003319717730636 | PMID 29025284 Get It

Data are limited on whether valvular calcification is associated with aortic wall stiffness. We tested whether aortic valve calcification (AVC) and/or mitral valve calcification (MVC) is inversely associated with aortic distensibility (AD). Cross-sectional study conducted in a subset of the Multi-Ethnic Study of Atherosclerosis (MESA) included 3676 MESA participants aged 44 to 84 years with AD measured with magnetic resonance imaging and with AVC and MVC measured with noncontrast cardiac computed tomography scans. Both AVC and MVC were divided into 3 categories: zero, < median values (low), and ≥ median values (high) for patients with nonzero values. Overall, 88% (n = 3256) and 92% (n = 3365) of participants had zero AVC and MVC, while 6% (n = 211) and 4% (n = 156) had low, and 6% (n = 209) and 4% (n = 155) had high values of AVC and MVC, respectively. The AVC was independently associated with AD after adjusting for age, gender, and ethnicity ( P = .035). No association was noted between AVC groups and AD after adjustment for all covariates or MVC groups and AD in any model.
Capacitive Sensing of Glucose in Electrolytes Using Graphene Quantum Capacitance Varactors
Ma, Rui , Zhen, Xue, Kudva, Yogish C. , Bühlmann, Philippe , Koester, Steven J. , Bühlmann, Philippe , Koester, Steven J , Zhang, Yao

Mayo Clinic

ACS Applied Materials & Interfaces | October 12, 2017 | Volume: 9 | Issue: 44 | Pages: 38863-38869

10.1021/acsami.7b14864 | PMID 29023095 Get It

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
Gangadhar, Tara C., Hwu, Wen-Jen , Postow, Michael A. , Hamid, Omid , Daud, Adil , Dronca, Roxana , Hodi, F. Stephen , Pavlick, Anna C. , Kluger, Harriet M. , Oxborough, Romina P., Yang, Aiming , Gazdoiu, Mihaela, Kush, Debra, Ebbinghaus, Scot, Salama, April K.S. , Daud, Adil I , Hwu, Wen‐Jen , Joseph, Richard W. , O'Day, Steven J

Mayo Clinic

Journal of Immunotherapy | October 12, 2017 | Volume: 40 | Issue: 9 | Pages: 334-340

10.1097/cji.0000000000000186 | PMID 29028788 Get It

KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484) was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Patients with unresectable stage III/IV melanoma that progressed after standard-of-care therapy, including ipilimumab and, if BRAF V600 mutant, a BRAF inhibitor, were eligible to receive pembrolizumab 2 mg/kg every 3 weeks. Response was assessed by immune-related response criteria by investigator review. Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. In the United States, 979 patients enrolled between April and September 2014. Of the 947 evaluable patients, 621 (65.6%) remained on treatment and transitioned to receive commercial pembrolizumab following approval by the Food and Drug Administration, whereas 326 (34.4%) discontinued, most commonly for disease progression (39.6%) or death (26.4%). Objective response rate was 14.5% (95% confidence interval, 12.2%–16.8%) in the treated population (n=947) and 22.1% (95% confidence interval, 18.8%–25.5%) in patients who had ≥1 response assessment reported (n=619). Twelve patients achieved complete response. One hundred eighty-one (19.1%) patients experienced ≥1 treatment-related AE, most commonly general disorders (8.0%), skin/subcutaneous tissue disorders (7.3%), and gastrointestinal disorders (6.4%); 29 (3.1%) patients experienced ≥1 grade 3/4 treatment-related AE. Immune-mediated AEs were also reported. There were no treatment-related deaths. The safety and efficacy observed in this expanded access program were consistent with those previously reported for similar populations and support the use of pembrolizumab for patients with advanced melanoma.